Skip to content

Total Revenue at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$730.8M-1.9%
Biogen logo
BiogenBIIB
$2.48B+1.9%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$814.5M+42.2%
Insmed logo
InsmedINSM
$305.96M+230%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
$0-100%
uniQure logo
uniQureQURE
$3.56M+127%

Other financials

Income statement

See full
Operating income-$57.3M-43.1%
Net income-$56.7M-44.4%
EPS (diluted)-$0.52+11.9%

Balance sheet

See full
Cash & equivalents$297.1M+41.1%
Total debt$20.7M-12.5%
Total equity$374.1M+27.1%
Total assets$422.9M+23.0%

Cash flow

See full
Operating cash flow-$47.2M-48.3%
CapEx$165.0K+31.0%
Free cash flow-$47.4M-48.2%

Valuation

See full
Market cap$910.66M+145%
Enterprise value$634.23M+244%
P/S112.5×-10.3×

Profitability

See full
Operating margin-1,315.2%-4,060pp
Net margin-1,062.3%-251,151pp
FCF margin-1,247.7%-9,569pp

Returns & leverage

See full
Return on equity-57.4%+2.2pp
Debt / equity0.1×0.0×
Current ratio13.1×+2.2×

Where this comes from

Reported directly by Solid Biosciences Inc. in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Solid Biosciences Inc.’s 10-K, filed March 23, 2023, on SEC EDGAR. View the filing →

Ask your AI about Solid Biosciences Inc.'s total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Solid Biosciences Inc.'s total revenue?
Solid Biosciences Inc. (SLDB) reported total revenue of $2.02M in Q4 2022.
How has Solid Biosciences Inc.'s total revenue changed year-over-year?
Solid Biosciences Inc.'s total revenue decreased by 40.6% year-over-year, from $3.41M to $2.02M.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.